📌 What is the AML Combo III Test?
A molecular genetic test used to detect key gene mutations and chromosomal abnormalities associated with Acute Myeloid Leukemia (AML). This test helps in diagnosing AML, guiding treatment, and determining prognosis.
📊 Normal Result
✔ Negative – No detectable AML-related mutations (suggests no high-risk genetic abnormalities)
🚨 Abnormal (Positive) Result May Indicate:
🔺 Presence of mutations linked to AML, such as:
FLT3-ITD (FMS-like tyrosine kinase 3 - Internal Tandem Duplication) → Poor prognosis
NPM1 (Nucleophosmin 1) → Favorable prognosis when FLT3 is negative
CEBPA (CCAAT Enhancer Binding Protein Alpha) → Associated with better outcomes
Other genetic markers commonly linked to AML progression
🎯 Purpose of the Test
✅ Confirms AML diagnosis by detecting specific mutations
✅ Guides personalized treatment, such as targeted therapies (e.g., FLT3 inhibitors)
✅ Assesses prognosis (favorable vs. high-risk mutations)
✅ Monitors disease progression and response to therapy
💡 Key Facts
🔹 AML is a fast-growing blood cancer affecting bone marrow and blood cells
🔹 Genetic mutations impact treatment options and survival rates
🔹 PCR and NGS (Next-Generation Sequencing) are used for precise mutation detection
🔹 Early detection & genetic profiling improve targeted therapy decisions